Market StrategyAmphastar expects to remain the only pre-filled syringe on the market despite increased competition.
Product GrowthBaqsimi, a brand asset with higher margins than corporate margins, shows growth potential, which could help mitigate pressures from other product lines.
ValuationAMPH shares, which have been under pressure (down ~38% since early-Nov) as investors anticipated the impact of increased competitive pressures, are approaching attractive valuation levels for entry.